Inmune Bio, Inc. - 8-K Filing
INmune Bio reported statistically significant treatment effects in MRI biomarker analyses for XPro™ (XPro1595) in its Phase 2 MINDFuL Alzheimer’s trial. The full mITT population showed a p=0.0028 and Cohen's d=0.46, while the inflammation-enriched subset had p=0.0098 and d=0.59. These results support XPro™'s mechanism targeting neuroinflammation in early Alzheimer’s disease. (Items: 8.01 Other Events, 9.01 Financial statements and Exhibits (d) Exhibits)
Tickers: $INMB